| 发明名称 |
USE OF TRANS-PALMITOLEATE IN IDENTIFYING AND TREATING METABOLIC DISEASE |
| 摘要 |
The present invention provides for a novel lipokine, trans-C16:1n7-palmitoleate, which also serves as a biomarker for metabolic status. More specifically, low concentrations of trans-C16:1n7-palmitoleate the serum indicates a risk of metabolic disease. Additionally, administering trans C16:1n7-palmitoleate to a subject (via pharmaceutical, nutraceutical, or other means), positively impacts glucose metabolism. |
| 申请公布号 |
US2016361284(A1) |
申请公布日期 |
2016.12.15 |
| 申请号 |
US201615248310 |
申请日期 |
2016.08.26 |
| 申请人 |
PRESIDENT AND FELLOWS OF HARVARD COLLEGE |
发明人 |
Mozaffarian Dariush;Cao Haiming;Hotamisligil Gokhan S. |
| 分类号 |
A61K31/201;A23L33/12 |
主分类号 |
A61K31/201 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
1. A method of reducing metabolic risk factor by decreasing triglyceride levels and/or raising HDL-C levels in a subject comprising administering to the subject a pharmaceutical, nutraceutical or dietary formulation, or dietary supplement, comprising trans-palmitoleate, wherein trans-palmitoleate is at least 6% of total fatty acids present in the formulation or supplement. |
| 地址 |
Cambridge MA US |
